Chairman, Women's Health Services, Henry Ford Health System
Obstetrics & Gynecology
Dr. Adnan Munkarah, MD
|
|
Give Review
Doctor Adnan Munkarah, MD is an expert in the field of Obstetrics & Gynecology. He researched medicine at Wayne State University School of Medicine. Wayne State University School of Medicine has a rank of 63 in research and a 85 in primary care He over the years received 4 awards: "Regional Top Doctor", "CMS Meaningful Use Stage 1 Certification", "Fellow (FACOG)" and "Super Doctor". Adnan Munkarah has written publications. He has 101 publications published with PubMed. The lastest paper is: 'Targeting of free fatty acid receptor 1 in EOC: A novel strategy to restrict the adipocyte-EOC dependence.' He is registered with Medicare.
Publications
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.
- Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional...
- The prognostic significance of histologic type in early stage cervical cancer - A multi-institutional study.
- Sox2 gene amplification significantly impacts overall survival in serous epithelial ovarian cancer.
- Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-instituti...
- Significance of lymphovascular space invasion in uterine serous carcinoma: what matters more; extent or presence?
- Tumor size is an independent predictor of lymph node metastasis and survival in early stage endometrioid endometrial cancer.
- Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: A multi-institution study.
- Protective effect of bisphosphonates on endometrial cancer incidence in data from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.
- Metformin limits the adipocyte tumor-promoting effect on ovarian cancer.
- Racial disparities in uterine clear cell carcinoma: a multi-institution study.
- Improved survival endpoints with adjuvant radiation treatment in patients with high-risk early-stage endometrial carcinoma.
- Improved Survival of Baby Boomer Women with Early-stage Uterine Cancer: A Surveillance, Epidemiology and End Results (SEER) Study.
- Is the Two-Tier Ovarian Serous Carcinoma Grading System Potentially Useful in Stratifying Uterine Serous Carcinoma? A Large Multi-Institutional Analysis.
- Prevalence and prognostic impact of lymphadenectomy and lymph node metastasis in clinically early-stage ovarian clear cell carcinoma.
- Risk of postoperative venous thromboembolism after minimally invasive surgery for endometrial and cervical cancer is low: a multi-institutional study.
- EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(wafa/cipa) and by inhibiting mutant p53.
- Prognostic impact of lymphadenectomy in uterine serous cancer.
- Clinical and Pathologic Characteristics of Serous Carcinoma Confined to the Endometrium: A Multi-institutional Study.
- Correlation of tumor size with other prognostic factors in uterine serous carcinoma: A large multi-institutional study.
- The impact of race on outcomes of patients with early stage uterine endometrioid carcinoma.
- Variants in the Signaling Protein TSAd are Associated with Susceptibility to Ovarian Cancer in BRCA1/2 Negative High Risk Families.
- A Detailed Study of Patients and Tumor Characteristics of Epithelial Ovarian Cancer in Saudi Women.
- Prognostic impact of marital status on survival of women with epithelial ovarian cancer.
- Clinical outcomes of adjuvant chemotherapy and vaginal brachytherapy with or without pelvic radiation for surgical stage I-II uterine serous carcinoma.
- Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma.
- Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis.
- The Prognostic Significance of Age in Surgically Staged Patients with Type II Endometrial Carcinoma.
- Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.
- Survival of women diagnosed with malignant, mixed mullerian tumors of the ovary (OMMMT).
- Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma.
- Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades.
- The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma.
- Cyclooxygenase-2 is expressed in human fibroblasts isolated from intraperitoneal adhesions but not from normal peritoneal tissues.
- Upper extremity deep vein thrombosis associated with indwelling peripheral venous catheters in gynecology oncology patients.
- The impact of c-kit and ki-67 expression on patients prognosis in advanced ovarian serous carcinoma.
- Hypoxia upregulates cyclooxygenase-2 and prostaglandin E(2) levels in human peritoneal fibroblasts.
- Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival.
- The controversies surrounding the management of uterine serous carcinoma.
- Hypoxia up-regulates the effects of prostaglandin E2 on tumor angiogenesis in ovarian cancer cells.
- Clinical update of smooth muscle tumors of the uterus.
- Increased expression of hypoxia-inducible factor 1alpha in type I and type II endometrial carcinomas.
- Patterns of loss of heterozygosity at 10q23.3 and microsatellite instability in endometriosis, atypical endometriosis, and ovarian carcinoma arising in association wit...
- The effects of the inhibition of inducible nitric oxide synthase on angiogenesis of epithelial ovarian cancer.
- Racial disparities in survival among patients with germ cell tumors of the ovary--United States.
- Impact of microsatellite instability (MSI) on survival in high grade endometrial carcinoma.
- Sensitization of ovarian cancer cells to cisplatin by genistein: the role of NF-kappaB.
- Image-guided percutaneous cryotherapy for the management of gynecologic cancer metastases.
- Fertility drugs and risk of ovarian cancer: dispelling the myth.
- Reduction of hypoxia-induced angiogenesis in ovarian cancer cells by inhibition of HIF-1 alpha gene expression.
- Myeloperoxidase serves as a redox switch that regulates apoptosis in epithelial ovarian cancer.
- The effects of combining docetaxel and cyclooxygenase-2 inhibitors on proliferation and apoptosis in epithelial ovarian cancer.
- Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer.
- Molecular typing of epithelial ovarian carcinomas using inflammatory markers.
- Fertility drugs and the risk of breast cancer: a meta-analysis and review.
- The prognostic impact of the ratio of positive lymph nodes on survival of epithelial ovarian cancer patients.
- Expression of GLUT-1 in epithelial ovarian carcinoma: correlation with tumor cell proliferation, angiogenesis, survival and ability to predict optimal cytoreduction.
- Suicide in women with gynecologic cancer.
- Prognosis and reproducibility of new and existing binary grading systems for endometrial carcinoma compared to FIGO grading in hysterectomy specimens.
- Disparities in treatment and survival between African American and White women with vaginal cancer.
- Prognostic impact of laterality in malignant ovarian germ cell tumors.
- Role of 12-lipoxygenase in regulation of ovarian cancer cell proliferation and survival.
- The impact of race on survival in uterine serous carcinoma: a hospital-based study.
- MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21(waf¹/cip¹).
- Detection and genotyping of human papilloma virus in cervical cancer specimens from Saudi patients.
- Modulation of redox signaling promotes apoptosis in epithelial ovarian cancer cells.
- Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: an epidemiological analysis.
- Outcomes of Patients With Uterine Serous Carcinoma Using the Revised FIGO Staging System.
- Clinical/pathologic features and patient outcome in early onset endometrial carcinoma: A population based analysis and an institutional perspective from the Detroit me...
- The role of frozen section in surgical staging of low risk endometrial cancer.
- Evaluating the significance of location of lymph node metastasis and extranodal disease in women with stage IIIC endometrial cancer.
- Vaginal recurrence more than 17 years after hysterectomy and adjuvant treatment for uterine carcinoma with successful salvage brachytherapy: a case report.
- Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma.
- Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary.
- Hysterectomy for uterine adenocarcinoma in the elderly: tumor characteristics, and long-term outcome.
- Clinical trials and progress with paclitaxel in ovarian cancer.
- Prognostic analysis of ovarian cancer associated with endometriosis.
- Validation of tumor size as staging variable in the revised International Federation of Gynecology and Obstetrics stage I leiomyosarcoma: a population-based study.
- Impact of marital status on survival among women with invasive cervical cancer: analysis of population-based surveillance, epidemiology, and end results data.
- Regulation of tumor angiogenesis by EZH2.
- Laparoscopic ovarian transposition before pelvic irradiation: a Saudi tertiary center experience.
- Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes.
- Analysis of the expression of human tumor antigens in ovarian cancer tissues.
- Update on ovarian cancer screening.
- PIK3CA alterations in Middle Eastern ovarian cancers.
- Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer.
- Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer.
- Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers.
- The racial disparity in outcomes in endometrial cancer: could this be explained on a molecular level?
- Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer.
- Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays.
- Asymptomatic uterine rupture of a cornual pregnancy in the third trimester: a case report.
- Does secondary surgical cytoreduction improve survival in women with advanced ovarian cancer?
- Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study.
- Radiation therapy with or without chemotherapy for cervical cancer with periaortic lymph node metastasis.
- COX-2: a protein with an active role in gynecological cancers.
- Modulation of the expression of vascular endothelial growth factor in human fibroblasts.
- Lycopene supplementation prevents the development of spontaneous smooth muscle tumors of the oviduct in Japanese quail.
- Critical evaluation of secondary cytoreduction in recurrent ovarian cancer.
- Targeting of free fatty acid receptor 1 in EOC: A novel strategy to restrict the adipocyte-EOC dependence.
Procedures Preformed
- Colpopexy
- Colposcopy
- Gynecologic Cancer Screening
- Hysterectomy - Laparoscopic
- View All
Doctors Specialties
- Gynecologic Oncology
- Obstetrics
- Gynecology
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
- Fellow (FACOG)
- Super Doctor
Education
-
University of Texas MD Anderson Cancer Center -
Wayne State University School of Medicine -
American University of Beirut Faculty of Medicine
Hospital
-
Henry Ford Hospital
Drug Facts
| NPI NUMBER | 1629166582 | |
| NPPES Provider LastName | MUNKARAH | |
| NPPES Provider FirstName | ADNAN | |
| NPPES Provider ZIPCode | 482022608 | |
| NPPES Provider State | MI | |
| Specialty Description | Gynecological/Oncology | |
| Total Claim Count | 48.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1629166582 |
| Last Name Of The Provider | MUNKARAH |
| First Name Of The Provider | ADNAN |
| View All |
Similar Doctors
|
Dr. Jay P. Shah, MD |
|
|
Dr. Shelly M. Seward, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gunter Deppe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Romeo H. Tabbilos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wooshin Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Thomas E. Buekers, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John M. Malone, MD |
|
Dr. Neil Simmerman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Raminder K. Khangura, MD |
|
|
Dr. Jacques Abramowicz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shyla R. Vengalil, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erica D. Louden, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonathan D. Oakes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laura M. Carney, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eline H. Wilson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vivek R. Katukuri, MD |
|
|
Dr. Ira S. Winer, MD |